In Q1 2023, Tang Capital Management held 61 positions worth $467.0M. They initiated 61 new positions. Their largest holding was ANAB ($44.2M).
Frequently asked questions
What stocks did Tang Capital Management own in Q1 2023?
Tang Capital Management held 61 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include ANAB, MIRM, EOLS, TARS, MRNA. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q1 2023?
Tang Capital Management's tracked biotech portfolio was worth $467.0M across 61 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q1 2023?
Tang Capital Management initiated 61 new positions in Q1 2023, including ANAB, MIRM, EOLS, TARS, MRNA and 56 more. They also increased 0 existing positions.
What did Tang Capital Management sell in Q1 2023?
Tang Capital Management did not fully exit any positions in Q1 2023.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →